CriticalCentrally acting psychostimulant×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)
Updated · Methodology
Mechanism
Methylphenidate is a mild central nervous system stimulant from the group of centrally acting sympathomimetics. It is thought to block the neuronal reuptake of noradrenaline and dopamine and to increase their release (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Phenelzine is a potent monoamine oxidase (MAO) inhibitor, and MAO inhibitors block the breakdown of noradrenaline and serotonin (phenelzine label, US Food and Drug Administration, FDA, Description and Precautions). According to the US phenelzine label, MAO inhibitors potentiate sympathomimetic drugs, which may result in hypertensive crisis. The label names methylphenidate among these sympathomimetics (FDA phenelzine label, Contraindications). Cytochrome P450 (CYP) enzymes do not metabolise methylphenidate to a clinically relevant extent (methylphenidate SmPC, AEMPS, section 4.5).
Symptoms
The main risk of the combination is hypertensive crisis (phenelzine label, US Food and Drug Administration, FDA, Contraindications; FDA methylphenidate label, sections 4 and 7). According to the US methylphenidate label, a crisis caused by combining stimulants with monoamine oxidase (MAO) inhibitors can lead to death, stroke, myocardial infarction, aortic dissection, eye complications, eclampsia, pulmonary oedema and renal failure (FDA methylphenidate label, section 7). With phenelzine, a hypertensive crisis presents with an occipital headache that may spread to the forehead, palpitations, neck stiffness or soreness, nausea, vomiting, sweating (sometimes with fever and sometimes with cold, clammy skin), dilated pupils and sensitivity to light. The heart rate may be fast or slow, sometimes with constricting chest pain. Intracranial bleeding has occurred with the rise in blood pressure, and some crises have been fatal (FDA phenelzine label, Warnings).
Management
The combination is contraindicated. The US phenelzine label prohibits sympathomimetic drugs in patients taking phenelzine and names methylphenidate (phenelzine label, US Food and Drug Administration, FDA, Contraindications). The US methylphenidate label contraindicates methylphenidate with monoamine oxidase (MAO) inhibitors and within 14 days of stopping them because of the risk of hypertensive crisis (FDA methylphenidate label, sections 4 and 7). The Spanish methylphenidate summary of product characteristics (SmPC) contraindicates methylphenidate with irreversible non-selective MAO inhibitors and within 14 days of stopping them (methylphenidate SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). Phenelzine is not authorised in Spain (AEMPS medicines register), so information on it comes from the US label. Start methylphenidate no earlier than 14 days after stopping phenelzine (FDA methylphenidate label, sections 4 and 7). No document gives an interval for the opposite order, when phenelzine is started after methylphenidate. Before prescribing methylphenidate, assess cardiovascular status, including blood pressure and heart rhythm. Then record blood pressure and pulse at every dose change and at least every 6 months (methylphenidate SmPC, AEMPS, sections 4.2 and 4.4). With phenelzine, check blood pressure often and stop phenelzine at once if palpitations or frequent headaches appear (FDA phenelzine label, Warnings). In a hypertensive crisis, stop phenelzine and start lowering blood pressure immediately. The US phenelzine label recommends phentolamine (a reported dose of 5 mg intravenously), given slowly to avoid an excessive fall in blood pressure. Manage fever with external cooling (FDA phenelzine label, Warnings).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Metilfenidato (nº registro 65148), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65148 (Concerta 18 mg, Janssen), revisión 03/2026, secciones 4.4, 4.5 y 5.1
- FDA: CONCERTA (methylphenidate hydrochloride) prescribing information (2026)– FDA, DailyMed setid 1a88218c-5b18-4220-8f56-526de1a276cd (Janssen), revisión 04/2026 (versión 30), secciones 4, 5.3 y 7